Hyderabad-based pharma giant Dr Reddy’s Ltd finalizes its largest acquisition by buying British Haleon Plc’s non-US nicotine replacement therapy (NRT) business for GBP 458 million. The deal includes brands like Nicotinell,

Dr Reddy's Laboratories has acquired Haleon's global Nicotine Replacement Therapy (NRT) portfolio, excluding the US, for GBP 458 million. This includes top brands like Nicotinell, Nicabate, Thrive, and Habitrol,

Drug maker Dr Reddy's Laboratories Ltd on Friday (September 27) said it has invested $620 million in its wholly-owned subsidiary, Dr Reddy’s Laboratories SA, Switzerland (DRL SA). This investment aligns with the company’s earlier board-approved fund infusion of up to ￡500 million ($640 million) to acquire the Nicotinell brand and related assets from the Haleon Group.

Dr Reddy's Laboratories on Monday said its Switzerland-based subsidiary has completed the acquisition of Haleon plc's global portfolio of consumer healthcare brands, outside of the US, in the Nicotine Replacement Therapy (NRT) category.

Dr Reddy's Laboratories has completed the acquisition of Haleon plc's global Nicotine Replacement Therapy (NRT) portfolio, including brands like Nicotinell, Nicabate, Thrive and Habitrol.